Literature DB >> 25773390

Correlation of Musashi-1, Lgr5, and pEGFR expressions in human small intestinal adenocarcinomas.

Yan Wang1, Cong-Qing Jiang, Li-Fang Fan.   

Abstract

Recent studies have revealed that Musashi-1 and Lgr5 (leucine-rich-repeat-containing G-protein-coupled receptor 5) were putative stem cell genes. The epidermal growth factor receptor (EGFR) has also been extensively studied; it was known as an oncogenic driver in cancers. Overexpressions of Musashi-1, EGFR, and Lgr5 have been reported in some tumor tissues and cell lines. In this study, we used immunohistochemical analysis to investigate the expression pattern of Musashi-1, Lgr5, and pEGFR in 38 small intestinal adenocarcinomas (SIAs) resection specimens, 20 matched normal specimens and tried to analyze the correlations among them. The positive rate of Musashi-1, Lgr5, and pEGFR in SIAs, respectively, was 71 % (27/38), 55 % (21/38), and 45 % (17/38). Compared with the adjacent normal small intestinal mucosa, Musashi-1, Lgr5, and pEGFR protein were overexpressed in SIAs (P< 0.05). Furthermore, Musashi-1 and Lgr5 expressions were significantly correlated with the depth of wall invasion (P = 0.0011, P = 0.0017, respectively). Musashi-1 expression was closely correlated with Lgr5 (P = 0.015, r = 0.392). However, pEGFR expression was not associated with age, gender, tumor size, differentiation, depth of invasion, lymphatic metastasis, TNM stage, and pEGFR expression was not correlated with Musashi-1 or Lgr5 (P > 0.05, r = 0.064; P > 0.05, r = 0.307, respectively). Thus, we suggest that Musashi-1, Lgr5, and pEGFR are overexpressed in human SIAs and may play roles in human SIA carcinogenesis and progression.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25773390     DOI: 10.1007/s13277-015-3288-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  50 in total

1.  Utility of preoperative chemoradiotherapy for advanced esophageal carcinoma.

Authors:  Junko Kuroda; Masashi Yoshida; Masaki Kitajima; Akio Yanagisawa; Toshiki Matsubara; Toshiharu Yamaguchi; Yoshiyuki Osamura; Keiichirou Ohta; Keisuke Kubota; Yoshifumi Beck; Yuichi Yamashita
Journal:  J Gastroenterol Hepatol       Date:  2012-04       Impact factor: 4.029

Review 2.  Small intestinal stem cell markers.

Authors:  Robert K Montgomery; David T Breault
Journal:  J Anat       Date:  2008-07       Impact factor: 2.610

3.  Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer.

Authors:  Hiroshi Uchida; Ken Yamazaki; Mariko Fukuma; Taketo Yamada; Tetsu Hayashida; Hirotoshi Hasegawa; Masaki Kitajima; Yuko Kitagawa; Michiie Sakamoto
Journal:  Cancer Sci       Date:  2010-03-24       Impact factor: 6.716

Review 4.  ErbB-targeted therapeutic approaches in human cancer.

Authors:  Carlos L Arteaga
Journal:  Exp Cell Res       Date:  2003-03-10       Impact factor: 3.905

5.  Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.

Authors:  Bouthaina S Dabaja; Dima Suki; Barbara Pro; Mark Bonnen; Jaffer Ajani
Journal:  Cancer       Date:  2004-08-01       Impact factor: 6.860

6.  Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo.

Authors:  Sripathi M Sureban; Randal May; Robert J George; Brian K Dieckgraefe; Howard L McLeod; Satish Ramalingam; Kumar S Bishnupuri; Gopalan Natarajan; Shrikant Anant; Courtney W Houchen
Journal:  Gastroenterology       Date:  2008-03-04       Impact factor: 22.682

7.  Expression of the Musashi1 gene encoding the RNA-binding protein in human hepatoma cell lines.

Authors:  Hong-Jin Shu; Takafumi Saito; Hisayoshi Watanabe; Jun-Itu Ito; Hiroaki Takeda; Hideyuki Okano; Sumio Kawata
Journal:  Biochem Biophys Res Commun       Date:  2002-04-26       Impact factor: 3.575

8.  CD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progression.

Authors:  Aymee Perez; David M Neskey; Judy Wen; Lutecia Pereira; Erika P Reategui; W Jarrard Goodwin; Kermit L Carraway; Elizabeth J Franzmann
Journal:  Oral Oncol       Date:  2012-12-20       Impact factor: 5.337

9.  Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  L Becker; Q Huang; H Mashimo
Journal:  Dis Esophagus       Date:  2009-06-22       Impact factor: 3.429

10.  Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival.

Authors:  Xiao-Song Wu; Hong-Qing Xi; Lin Chen
Journal:  World J Surg Oncol       Date:  2012-11-15       Impact factor: 2.754

View more
  5 in total

Review 1.  RNA Binding Proteins in Intestinal Epithelial Biology and Colorectal Cancer.

Authors:  Priya Chatterji; Anil K Rustgi
Journal:  Trends Mol Med       Date:  2018-04-05       Impact factor: 15.272

2.  Overexpression of Musashi-1 protein is associated with progression and poor prognosis of gastric cancer.

Authors:  Zhangxuan Shou; Xue Jin; Xujun He; Zhongsheng Zhao; Yuan Chen; Meihua Ye; Jiong Yao
Journal:  Oncol Lett       Date:  2017-03-21       Impact factor: 2.967

Review 3.  Targeting LGR5 in Colorectal Cancer: therapeutic gold or too plastic?

Authors:  R G Morgan; E Mortensson; A C Williams
Journal:  Br J Cancer       Date:  2018-05-30       Impact factor: 7.640

4.  Lgr5-positive cells in the lung and their clinical significance in patients with lung adenocarcinoma.

Authors:  Xiaohan Zhang; Miao Xu; Shixin Su; Zeqi Zhou; Hong Yang; Suwen Zhao; Danni Zeng; Kaiying Yang; Yanan Liu; Lijing Wang; Jiangchao Li
Journal:  Mol Clin Oncol       Date:  2016-06-14

5.  Knockdown of MSI1 inhibits the proliferation of human oral squamous cell carcinoma by inactivating STAT3 signaling.

Authors:  Chen-Fei Wang; Hong-Chuang Zhang; Xin-Mei Feng; Xiao-Meng Song; Yu-Nong Wu
Journal:  Int J Mol Med       Date:  2019-05-06       Impact factor: 4.101

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.